Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Aplagon is a clinical-stage biopharmaceutical company developing first-in-class therapies for thromboinflammatory diseases. Built on pioneering research by Prof. Riitta Lassila’s group at Wihuri Research Institute in Finland, Aplagon’s lead candidate, APAC, is a heparin proteoglycan mimetic. With a strong scientific foundation, APAC is now advancing through clinical studies for two cardiovascular indications, aiming to pro...
Aplagon is a clinical-stage biopharmaceutical company developing first-in-class therapies for thromboinflammatory diseases. Built on pioneering research by Prof. Riitta Lassila’s group at Wihuri Research Institute in Finland, Aplagon’s lead candidate, APAC, is a heparin proteoglycan mimetic. With a strong scientific foundation, APAC is now advancing through clinical studies for two cardiovascular indications, aiming to provide innovative solutions for patients with unmet medical needs.

List your booth number for exhibitions, ask us